Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Ridderstråle, Martin ^a   Svaerd, Robbyna ^b   Zeller, Cordula ^c   Kim, Gabriel ^c   Woerle, Hans J ^c   Broedl, Uli C ^c  

^a STENO DIABETES CENTER   (Denmark)

^b Boehringer Ingelheim AB   (Sweden)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Blood pressure; Body weight; Empagliflozin; Glimepiride; Glycemic control; Macrovascular; Microvascular; SGLT2 inhibitor; Sulfonylurea; Type 2 diabetes

Indexed keywords

EMPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CELL FUNCTION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

AGED; BENZHYDRYL COMPOUNDS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RESEARCH DESIGN; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883452474     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-129     Document Type: Article

References (47)

1. DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795. 10.2337/db09-9028, 2661582, 19336687.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379. 10.2337/dc12-0413, 3357214, 22517736, American Diabetes Association (ADA).
3. International Diabetes Federation Clinical guidelines task force global: guideline for type 2 diabetes 2012, http://www.idf.org/sites/default/files/IDF%20T2DM%20Guideline.pdf, International Diabetes Federation.
4. Braga MF, Casanova A, Teoh H, Gerstein HC, Fitchett DH, Honos G, McFarlane PA, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA, Diabetes Registry to Improve Vascular Events [DRIVE] Investigators Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. Int J Clin Pract 2012, 66:457-464. 10.1111/j.1742-1241.2012.02894.x, 22452524, Diabetes Registry to Improve Vascular Events [DRIVE] Investigators.
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012. 10.1001/jama.281.21.2005, 10359389.
6. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
7. Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations. Vasc Health Risk Manag 2012, 8:463-472. 3448454, 23028231.
8. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443. 10.1056/NEJMoa066224, 17145742, ADOPT Study Group.
9. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC, UK Prospective Diabetes Study (UKPDS) Group UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998, 15:297-303. UK Prospective Diabetes Study (UKPDS) Group.
10. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003, 26:2231-2237. 10.2337/diacare.26.8.2231, 12882841.
11. Alvarsson M, Sundkvist G, Lager I, Berntorp K, Fernqvist-Forbes E, Steen L, Orn T, Holberg MA, Kirksaether N, Grill V. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab 2008, 10:421-429. 10.1111/j.1463-1326.2007.00719.x, 17394534.
12. Alvarsson M, Berntorp K, Fernqvist-Forbes E, Lager I, Steen L, Orn T, Grill V. Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. Rev Diabet Stud 2010, 7:225-232. 3061612, 21409314.
13. Shin MS, Yu JH, Jung CH, Hwang JY, Lee WJ, Kim MS, Park JY. The duration of sulfonylurea treatment is associated with β-cell dysfunction in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2012, 14:1033-1042. 10.1089/dia.2012.0144, 22958196.
14. Marrett E, Radican L, Davies MJ, Zhang Q. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes 2011, 4:251. 10.1186/1756-0500-4-251, 3148563, 21777428.
15. Marrett E, Stargardt T, Mavros P, Alexander CM. Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab 2009, 11:1138-1144. 10.1111/j.1463-1326.2009.01123.x, 19758360.
16. Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med 2009, 26:416-424. 10.1111/j.1464-5491.2009.02696.x, 19388973.
17. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004, 27:1218-1224. 10.2337/diacare.27.5.1218, 15111553.
18. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM, Evans M. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 2012, 35:1279-1284. 10.2337/dc11-1277, 3357221, 22511257.
19. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909. 10.1136/bmj.b4909, 2803744, 20061358.
20. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011, 34(suppl 2):S132-S137. 3632150, 21525444.
21. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J, ADVANCE Collaborative Group Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813-1821. 10.1681/ASN.2008121270, 2723977, 19443635, ADVANCE Collaborative Group.
22. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
23. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589. 10.1056/NEJMoa0806470, 18784090.
24. National Diabetes Information Clearinghouse (NDIC) National diabetes statistics 2011, http://diabetes.niddk.nih.gov/dm/pubs/statistics/, National Diabetes Information Clearinghouse (NDIC).
25. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006, 174:169-174. 10.1503/cmaj.050748, 1329454, 16415461.
26. Rosenstock J, Marx N, Kahn S, Zinman B, Kastelein J, Lachin J, Bluhmki E, Patel S, Johansen OE, Woerle HJ. Cardiovascular outcome trials in type 2 diabetes and the sulfonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013, 10:289-301. 10.1177/1479164112475102, 23449634.
27. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012, 14:83-90. 10.1111/j.1463-1326.2011.01517.x, 21985634.
28. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010, 27:136-142. 10.1111/j.1464-5491.2009.02894.x, 20546255.
29. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, Woerle H. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013, 15:613-621. 10.1111/dom.12073, 23356556.
30. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle H. A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013, 15:721-728. 10.1111/dom.12081, 23398530.
31. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC. Empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a randomised, 24-week, double-blind, placebo-controlled parallel group trial with sitagliptin as active comparator. Lancet Diabetes Endocrinol in press.
32. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, Woerle HJ. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab epub ahead of print.
33. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin improves glycemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab epub ahead of print.
34. Häring H-U, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ. Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM). Diabetes 2013, 62(suppl 1):A282. [1092-P].
35. Häring H-U, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care epub ahead of print.
36. Rosenstock J, Jelaska A, Wang F, Kim G, Broedl UC, Woerle HJ. Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM). Diabetes 2013, 62(suppl 1):A285. [1102-P].
37. Ferrannini E. Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant 2010, 25:2041-2043. 10.1093/ndt/gfq249, 20466683.
38. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC. Empagliflozin in patients with type 2 diabetes mellitus (T2DM) and renal impairment (RI). Diabetes 2013, 62(suppl 1):A286. [1104-P].
39. Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC. Long-term safety and efficacy of empagliflozin, sitagliptin and metformin: an active-controlled, parallel group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care in press.
40. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012, 5:313-327. 3437808, 22977310.
41. DeFronzo RA, Davidson JA, del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012, 14:5-14. 10.1111/j.1463-1326.2011.01511.x, 21955459.
42. Jelsing J, Vrang N, Mark M, Mayoux E, Klein T. The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin has a durable effect on the restoration of glucose homeostasis by preserving beta-cell mass in zucker diabetic fatty rats [abstract]. Diabetes 2012, 61(Suppl 1):A261.
43. Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012, 9:117-123. 10.1177/1479164112441190, 22381403.
44. Basile J. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013, 27:280-286. 10.1016/j.jdiacomp.2012.12.004, 23375850.
45. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60683-2/fulltext. epub ahead of print.
46. Nauck MA, del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011, 34:2015-2022. 10.2337/dc11-0606, 3161265, 21816980.
47. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013, 3:1-150. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.